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The mammalian target of rapamycin complex 1
(mTORC1) integrates signals important for cell
growth, and its dysregulation in neural stem cells
(NSCs) is implicated in several neurological disorders
associated with abnormal neurogenesis and brain
size. However, the function of mTORC1 on NSC
self-renewal and the downstream regulatory mecha-
nisms are ill defined. Here, we found that genetically
decreasing mTORC1 activity in neonatal NSCs pre-
vented their differentiation, resulting in reduced line-
age expansion and aborted neuron production.
Constitutive activation of the translational repressor
4E-BP1, which blocked cap-dependent translation,
had similar effects and prevented hyperactive
mTORC1 induction of NSC differentiation and pro-
moted self-renewal. Although 4E-BP2 knockdown
promoted NSC differentiation, p70 S6 kinase 1 and
2 (S6K1/S6K2) knockdown did not affect NSC differ-
entiation but reduced NSC soma size and prevented
hyperactivemTORC1-induced increase in soma size.
These data demonstrate a crucial role of mTORC1
and 4E-BP for switching on and off cap-dependent
translation in NSC differentiation.INTRODUCTION
Neural stem cells (NSCs) lie at the core of brain development
and repair, and alterations in NSC self-renewal and differentia-
tion can have major consequences on brain function at any
stage of life (Gage, 2000). As a result, a series of extracellular
signals tightly regulates NSC self-renewal and differentiation
at different stages of brain development (Shi et al., 2008).
Many of these extracellular signals subsequently activate the
mammalian target of rapamycin complex 1 (mTORC1) signaling
pathway, which is an intracellular hub of translational regulationC(Tee and Blenis, 2005; Laplante and Sabatini, 2012). mTORC1 is
of particular interest because it is dysregulated and most often
hyperactive in several neurodevelopmental disorders associ-
ated with neurocognitive and psychiatric impairments, such as
tuberous sclerosis complex, fragile X syndrome, and autism
spectrum disorder (Inoki et al., 2005; Hoeffer et al., 2012;
Hoeffer and Klann, 2010; Santini and Klann, 2011; Wang and
Doering, 2013).
Despite a wealth of studies related to the impact of hyper-
active mTORC1 on brain development in vivo and to some
extent NSC behavior in vitro (Magri et al., 2011; for review,
see Feliciano et al., 2013b; Magri and Galli, 2013), very little
is known about the physiological function of mTORC1 on
NSC self-renewal and neuron production in vivo. mTORC1
function has been examined using a pharmacological approach
by injecting the mTOR blocker rapamycin, either alone or in
conjunction with a ligand that activates the mTORC1 pathway
(Paliouras et al., 2012; Magri and Galli, 2013). Rapamycin is
important to test because of its clinical value to treat disorders
associated with hyperactive mTORC1 activity, such as tuber-
ous sclerosis complex (Ehninger and Silva, 2011), but it does
not distinguish cell-autonomous from non-cell-autonomous
effects and may also block mTOR complex 2. Adding to our
knowledge gap is the lack of information related to the direct
downstream effectors mediating hyperactive mTORC1 effects
on NSC self-renewal. Addressing this issue is of high funda-
mental and clinical significance for identifying novel therapeutic
targets to prevent the negative effects of hyperactive mTORC1
on NSCs in several neurodevelopmental disorders, as well as in
aging (Lamming et al., 2013; Johnson et al., 2013; Inoki et al.,
2005).
Here, we explore mTORC1 and its downstream effectors’
function on neonatal NSCs in the subventricular zone (SVZ), a
neurogenic niche that confers a high degree of plasticity for cir-
cuit remodeling and repair after birth (Mitchell et al., 2004; Sanai
et al., 2011; Feliciano et al., 2012). In vivo electroporation in
neonates was used to transfect expression or knockdown vec-
tors selectively in NSCs lining the lateral wall of the lateral
ventricle and manipulate the activity of mTORC1 and its
downstream effectors, the translational repressors 4E-BPs andell Reports 5, 433–444, October 31, 2013 ª2013 The Authors 433
Figure 1. Basal Level of mTORC1 Activity in Proliferative NSCs and TACs in the Neonatal SVZ
(A) Diagram illustrates Rheb-mTORC1 signaling pathway. Rapamycin (RAPA) blocks mTORC1 activity.
(B and C) pS6 immunostaining (S240/S244, red in B) or p4E-BP1/BP2 immunostaining (red in C) with DAPI (blue) counterstain is shown in coronal sections
containing the SVZ along the lateral side of the lateral ventricle (LV) from a P9mouse. Rapamycin was given at 0.5 mg/kg every 2 days from P5 to P9. Str, striatum.
Scale bars, 70 mm.
(D) Bar graphs show the percentage (%) of SVZ cells expressing pS6 and p4E-BP1/BP2 at P9 under control and following rapamycin treatment (n = 4 mice for
each condition). Asterisks indicate statistical significance (***p < 0.001) by Student’s t test.
(E) Immunostaining is shown for Ki67 (blue) and pS6 (red), and GFP (green) in the SVZ of a coronal section of a P9 hGFAP-GFPmouse. The solid arrowheads point
to pS6 expression in a GFP+ cell.
(F) Immunostaining is presented for pS6 (red) and Mash1 (blue) in the SVZ of a P9 coronal section.
(G) Immunostaining is shown for pS6 (red), Mash1 (blue), and DCX (green) in the SVZ of a P9 coronal section.
(H) Bar graphs show the percentage (%) of each cell population expressing pS6 and p4E-BP1/BP2.
(I) Immunostaining is shown for p4E-BP1/BP2 (red), Mash1 (blue), and GFP (green) with DAPI (gray) counterstain in the SVZ of a coronal section of a P9 hGFAP-
GFP mouse.
(J) Diagram illustrates cell lineage in the neonatal SVZ and the cellular distribution of proliferative marker Ki67 and active mTORC1 effectors, p4E-BP1/BP2
and pS6.
Scale bars, 20 mm (E–G and I). Error bars indicate SEM (n = 3–4 mice for staining and analysis). See also Figure S1.S6K1/S6K2. We found that decreasing mTORC1 activity pre-
vented the generation of intermediate progenitors, leading to
reduced neuron production. Consistent with this finding,
increasing mTORC1 activity did not induce NSC proliferation
but induced its terminal differentiation into highly proliferative in-
termediate progenitors, leading to an apparent increase in the
number of proliferative cells. The hyperactive mTORC1 effect
was mediated by inhibition of 4E-BP2, but not S6K1/S6K2,
and activation of cap-dependent translation in regulating NSC
self-renewal. These findings suggest that altering mTORC1
activity in NSCs affects neuron production and density that
may lead to circuit instability.434 Cell Reports 5, 433–444, October 31, 2013 ª2013 The AuthorsRESULTS
mTORC1 Is Active in Proliferative NSCs and TACs in the
Neonatal SVZ
To examine basal mTORC1 activity in NSCs, we immunostained
the neurogenic SVZ on postnatal day 8 (P8)–P9 for phosphory-
lated 4E-BP1/BP2 (p4E-BP1/BP2) and phosphorylated ribo-
somal protein S6 (pS6, Serine [S] 240/244), which are both
readouts of mTORC1 activity (Laplante and Sabatini, 2012) (Fig-
ures 1A–1C). In the SVZ, NSCs self-renew and generate transit-
amplifying cells (TACs) that are highly proliferative and contribute
to neuronal lineage amplification and neuroblast generation
(Figure 1J) (Merkle and Alvarez-Buylla, 2006). The SVZ can be
divided into three regions, dorsal, lateral, and ventral (Fig-
ure S1A), which display different distributions of the different
cell types (Figure S1B). For consistency, analysis was performed
in the lateral SVZ.We found that p4E-BP1/BP2 and pS6were ex-
pressed in a subset of SVZ cells, the percentage of which was
significantly reduced by treatment with the mTORC1 blocker
rapamycin (Figures 1B–1D), validating the mTORC1 depen-
dence of these signals. Among the different cell types, prolifera-
tive (Ki67+) NSCs identified by expression of GFP driven by the
human glial fibrillary acidic protein (hGfap) promoter (Pastrana
et al., 2009) expressed pS6 (Figures 1E and 1H). The majority
of TACs (75%) identified by expression of Mash1 (Parras et al.,
2004) and 10% of neuroblasts identified by doublecortin
(DCX) expression immunostained positive for pS6 (Figures 1F–
1H and S1B). The cellular distribution of p4E-BP1/BP2 was
similar to that of pS6 except for neuroblasts, the majority of
which expressed p4E-BP1/BP2 (Figures S1C and S1D). These
findings are summarized in a diagram in Figure 1J.
Reduction of mTORC1 Activity in NSCs and TACs Limits
Neuron Production
To investigate the function of mTORC1 on neuron production
in vivo, we used in vivo neonatal electroporation. P0 littermate
pups were transfected with a conditional plasmid encoding a
small hairpin RNA (shRNA) directed against Ras homolog en-
riched in brain (Rheb), a direct activator of mTORC1, or encoding
a control-scrambled shRNA (Lacar et al., 2010; Boutin et al.,
2008; Chesler et al., 2008) (Figures 2A and 2B). The cells targeted
by electroporation were quiescent and proliferative NSCs along
the lateral wall of the lateral ventricle. Once in NSCs, plasmids
were passed on to their progeny, TACs and neuroblasts, which
migrate to their final location (i.e., the olfactory bulb [OB]) in
about 2weeks (Figures 2A and 2C). To induce shRNA expression
constitutively, we coelectroporated the conditional shRNA
constructs with a Cre recombinase (Cre)-encoding plasmid
(pCAG-Cre, Figure 2B). A plasmid encoding the red fluorescent
protein tdTomato (pCAG-RFP) was included as a reporter to
label cells, resulting in coelectroporation of three vectors.
Coelectroporation of three (pCAG-RFP plus pCAG-GFP plus
pCAG-BFP, blue fluorescent protein) and two vectors resulted
in 86.2% ± 1.2% and 94.4% ± 0.7% colocalization per cell,
respectively (mean ± SEM, n = 3 mice each, Figures S2A and
S2B, images for two vectors), resulting in an underestimation
of reported effects by 14% and 6%, respectively. Two weeks
following electroporation with control shRNA, RFP+ neurons
born from transfected NSCs in the SVZ had migrated into the
OB as expected (Figure 2D) (Lacar et al., 2010; Platel et al.,
2010). Rheb knockdown led to decreased mTORC1 activity in
transfected Neuro2a cells in vitro as well as in transfected SVZ
cells and newborn OB neurons in vivo (Figures S2C–S2I).
DecreasedmTORC1 activity resulted in a significant 40% reduc-
tion in the density of RFP-expressing neurons in the OB (Figures
2D and 2E). To ensure that the reduction in newborn neuronswas
not due to alteration of neuroblast development, we knocked
down mTORC1 activity specifically in neuroblasts. To do this,
the conditional Rheb shRNA vector was used in Dlx5/Dlx6-Cre
mice because Dlx5/Dlx6 expression is restricted to neuroblastsCin this system (Figures 2F–2H) (Kohwi et al., 2007). The condi-
tional shRNA vector contains a floxed GFP (see diagram in Fig-
ure 2B), which is expressed in transfected SVZ cells, but is lost
in newborn neurons following GFP excision in Dlx5/Dlx6-Cre-
expressing neuroblasts (Figures 2G and 2H). In addition,
cotransfection of a conditional RFP demonstrated efficient
Cre-mediated recombination in newborn neurons (Figure 2H).
In Dlx5/Dlx6-Cre mice, decreased mTORC1 activity in neuro-
blasts did not alter the number of newborn neurons in the OB
(Figures 2I and 2J). Collectively, these data suggest that
mTORC1 activity in the SVZ controls NSC self-renewal or TAC
proliferation and, therefore, regulates the production of newborn
neurons.
mTORC1 Activity Is Required for TAC Generation
To determine whether mTORC1 acted on NSC self-renewal or
TAC proliferation, we electroporated Rheb shRNA in NSCs at
P0 and quantified total and proliferative TACs in the SVZ as a
proportion of transfected cells at 3 and 7 days postelectropora-
tion (DPE). Immunostaining was performed using an Alexa
633-conjugated secondary antibody (pseudocolored green in
Figure 3) allowing us to distinguish the staining from GFP and
RFP-labeled cells. By 3 DPE, proliferative NSCs transfected
with the control shRNA generated Mash1+ TACs (Figure 3B).
Rheb knockdown led to a significant 60% decrease in the per-
centage of transfected cells expressing Mash1 (Figures 3B, 3D,
and S3B at 7 DPE). There was also a 50% decrease in the per-
centage of transfected cells expressing Ki67 (Figures 3C–3F,
S3A, and S3B at 7DPE), but no change in the proportion of trans-
fected TACs expressing Ki67 or EdU (Figures 3E and 3F), sug-
gesting that Rheb knockdown did not affect TAC proliferation.
The Rheb knockdown effect was mTORC1 dependent because
it was reproduced by a shRNA directed to Raptor, a necessary
mTOR binding partner in mTORC1 (Figures 3G and S3C–S3F),
and by pharmacological inhibition of mTORC1 activity with rapa-
mycin (Figures 3H–3K). In addition, consistent with mTORC1’s
role as a master regulator of cell growth, Rheb knockdown re-
sulted in a significant 17% decrease in the soma size of trans-
fected NSCs (±4 SEM; p < 0.05, Student’s t test; n = 3 mice
each; data not shown). Collectively, these results suggest that
baseline mTORC1 activity is required for Mash1+ TAC genera-
tion from NSCs.
mTORC1 Drives NSC Differentiation at the Expense of
Self-Renewal
Because mTORC1 activity is upregulated in several neurological
diseases (Chong et al., 2010), we explored the outcome of
increasingmTORC1 activity by expressing a constitutively active
Rheb (RhebCA) into NSCs at P0 (Figure 4) (Lafourcade et al.,
2013; Maehama et al., 2008). As controls, littermates were elec-
troporated with pCAG-GFP vector. Both conditions were coe-
lectroporated with GFP (pCAG-GFP) as a reporter. Although
the control condition has GFP, we injected additional pCAG-
GFP to match the plasmid concentration between the two con-
ditions. RhebCA expression led to a significant increase in the
percentage of transfected SVZ cells expressing pS6 at 3 DPE
that was rapamycin sensitive, indicating mTORC1 activation
(Figures S4A and S4B). We then found that RhebCA-inducedell Reports 5, 433–444, October 31, 2013 ª2013 The Authors 435
Figure 2. Genetically Decreasing mTORC1 Activity in NSCs and Mash1+ TACs Leads to Decreased Neuron Production
(A) Diagram illustrates neonatal electroporation at P0 in NSCs of the SVZ along the lateral side of the lateral ventricle and subsequent integration of plasmid-
containing neurons in the OB by 2 weeks postelectroporation (WPE). The yellow symbol illustrates current injection.
(B) Vectors used in (C)–(E) in wild-type mice are shown.
(C) Diagram illustrates that plasmids are electroporated into NSCs and passed on to their daughter cells.
(D) Images present hemisected coronal OB sections containing neurons with RFP and scrambled (Scr) or Rheb shRNA in wild-type mice.
(E) Bar graphs show the corresponding percentage (%) of normalized RFP+ cells in the OB with Scr shRNA (black) or Rheb shRNA (gray). Asterisks indicate
statistical significance (****p < 0.0001) by Student’s t test.
(F) Vectors used in (G)–(J) in wild-type mice are presented.
(G) Diagram shows that electroporation of a conditional Cre-Lox shRNA and RFP vector results in Rheb shRNA and RFP expression selectively in neuroblasts in
Dlx5/Dlx6-Cre mice.
(H) Image presents a sagittal section containing GFP+ cells (GFP frompSico vector) in the SVZ andRFP+ cells (RFP from the conditional RFP reporter) in theOB at
14 DPE in Dlx5/Dlx6-Cre mice. Cells acquire RFP upon Cre excision of the LoxP GFP cassette in neuroblasts known to express Dlx5/Dlx6 and progressively lose
GFP surrounded by LoxP sites in the conditional shRNA vector. The migratory route from the SVZ to OB is not visible in this section. Inset is a zoom of RFP+ and
GFP+ cells in the RMS of the OB.
(I and J) Images show hemisected OB sections (I) and normalized bar graphs of electroporated neurons (J) as in (D) and (E), but in Dlx5/Dlx6-Cre mice. NS, not
significant.
Scale bars, 100 mm (D and I) and 200 mm (H). Error bars indicate SEM (n = 3–4 mice for staining and analysis). See also Figure S2.increased mTORC1 activity in NSCs had opposite effects to
those observed with Rheb knockdown. At both 3 and 7 DPE,
there was a significant increase in the percentages of RhebCA-
transfected cells expressing Mash1 and Ki67 (Figures 4A–4C
and S4C–S4E at 7 DPE). The effect of RhebCA expression was
due to mTORC1 activity because it was prevented by rapamycin
treatment (Figure 4C).
The effect of hyperactive mTORC1 on NSCs could be ex-
plained by either causing quiescent NSCs to proliferate and
generate TACs cells or inducing NSC differentiation into two
TACs at the expense of self-renewal. To distinguish NSCs from436 Cell Reports 5, 433–444, October 31, 2013 ª2013 The Authorstheir daughter cells, we quantified the proliferative index of
NSCs in the SVZ in hGfap-GFP mice (Platel et al., 2009). The
lack of increase in the Ki67 proliferative index of RhebCA-trans-
fected NSCs at 3 DPE argues against an increase in NSC
proliferation with hyperactive mTORC1 (Figure 4D). To further
investigate RhebCA effect on NSC self-renewal, we examined
the clonal behavior of NSCs in vitro. NSCs were transfected
in vivo with RFP and RhebCA or a control GFP vector prior to
plating as an adherent single-cell culture (Figure 4E). At 1 day
in vitro (DIV), RFP+ cells were found as single cells, with 93%–
95% immunostaining positive for GFAP, but not for Mash1, in
Figure 3. Baseline mTORC1 Activity Is Required for Mash1+ TAC Generation from NSCs
(A) Diagram illustrates Rheb-mTORC1 signaling pathway, in which Raptor is a component of mTORC1 and necessary for its activity. Rheb directly activates
mTORC1.
(B and C) RFP (red) and immunostaining for Mash1 (pseudocolored green in B) and Ki67 (pseudocolored green in C) are shown in the SVZ in coronal sections in 3
DPE mice electroporated with Scr shRNA or Rheb shRNA into NSCs at P0. pCAG-RFP was coelectroporated to label SVZ cells in both conditions. Arrowheads
point to Mash1+ and Ki67+ cells. In these images, cells expressing GFP from the shRNA vector (due to the absence of Cre coexpression) were not present,
allowing us to pseudocolor Alexa Fluor 633-fluorescent immunostaining in green.
(D) Bar graphs show the percentage (%) of RFP+ cells in the SVZ expressing Mash1 or Ki67 under control (Scr shRNA, black) and Rheb knockdown condition
(gray).
(E) RFP (red) and immunostaining for Mash1 (green) and EdU (blue) are shown in the SVZ in coronal sections in 3 DPEmice electroporated with Scr shRNA at P0.
(F) Bar graphs show the percentage (%) of Mash1+ RFP+ cells in the SVZ expressing Ki67 or EdU under control (black) and Rheb knockdown condition (gray).
(G) Bar graphs show the percentage (%) of RFP+ cells in the SVZ expressing Mash1 or Ki67 (gray) under control (Scr shRNA, black) and Raptor knockdown
condition (gray) at 7 DPE.
(H) Diagram illustrates the rapamycin protocol.
(I and J) Staining for DAPI (blue) and Mash1 (red in I) or Ki67 (red in J) in the SVZ in coronal sections of mice treated with saline or rapamycin is presented.
(K) Bar graphs show the percentage (%) of SVZ cells expressingMash1 or Ki67 following saline (black) or rapamycin injections (gray). For the saline and rapamycin
conditions, the percentages of cells were obtained with respect to the total DAPI+ (nuclear stain) cells in the SVZ along the lateral side of the lateral ventricle.
Scale bars, 20 mm (B, C, I, and J) and 10 mm (E). Asterisks indicate statistical significance (**p < 0.01; ****p < 0.0001) by Student’s t test. Error bars are SEM (n = 4–5
mice per condition). See also Figure S3.both conditions (Figures 4F and 4H). At 4 DIV, NSCs generated
clusters containing two or more RFP+ cells (Figures 4G and 4I).
In the control condition, 80% of the two-cell clusters contained
either two GFAP+ or a GFAP+ cell and a Mash1+ TAC, suggest-
ing that NSCs underwent symmetric and asymmetric self-
renewal, respectively (Figure 4J). In the hyperactive mTORC1Ccondition, cluster size and the percentage of RFP+ cells ex-
pressing Mash1 significantly increased, suggesting lineage
amplification (Figures 4G and 4I). In addition, 81% of the two-
cell clones contained two Mash1+ TACs (Figure 4J), indicating
that hyperactive mTORC1 drives NSCs to terminally differentiate
into TACs at the expense of self-renewal.ell Reports 5, 433–444, October 31, 2013 ª2013 The Authors 437
Figure 4. Increased mTORC1 Activity Drives NSC Differentiation into TACs at the Expense of Self-Renewal
(A and B) GFP (green) and immunostaining for Mash1 (red in A) and Ki67 (red in B) are shown in the SVZ in coronal sections in 3 DPEmice electroporated with RFP
or RhebCA into NSCs at P0. pCAG-GFP was coelectroporated to label SVZ cells in both conditions.
(C) Bar graphs show the percentage (%) of GFP+ cells in the SVZ expressing Mash1 or Ki67 under control (black), RhebCA condition (gray), or RhebCA with
rapamycin treatment (dark gray). RhebCA and RhebCA with saline gave similar results. Data were pooled.
(D) Bar graphs show the percentage (%) of transfected NSCs expressing Ki67 under control (black) and RhebCA condition (gray) at 3 DPE. For these experiments,
RhebCA and RFP were electroporated in NSCs of hGfap-GFP mice, allowing us to distinguish NSCs from their daughter cells.
(E) Diagram illustrates the in vitro experimental protocol.
(F) Immunostaining for GFAP (green) and Mash1 (blue) is shown in RFP+ NSCs at 1 DIV that were transfected with control vector and plated 1 DPE.
(G) Immunostaining for GFAP (green) andMash1 (blue) is presented in RFP+ two-cell clusters at 4 DIV that were transfected with either a control vector or RhebCA
and plated 1 DPE. The insets illustrate Mash1 immunostaining.
(H) Bar graph shows the percentage (%) of transfected cells expressing GFAP at 1 DIV.
(I) Bar graph presents the average cluster size at 4 DIV.
(J) Bar graph shows the GFAP+ and Mash1+ cell composition of the two-cell clusters at 4 DIV.
Asterisks indicate statistical significance (**p < 0.01; ***p < 0.001; ****p < 0.0001) by Student’s t test (C, D, H, and I) and Fisher’s exact test (J) (n = 3–4mice for each
time point). Scale bars, 20 mm (A, B, and F). Error bars are SEM. See also Figure S4.4E-BP2 Mediates mTORC1-Induced Differentiation
through Cap-Dependent Translation
Finally, we aimed to better understand the mechanisms underly-
ing mTORC1’s effects on NSC differentiation. We examined the
contribution of S6K1/S6K2 and 4E-BPs to mTORC1 effect on
NSC differentiation and soma size (Figure 5A). S6K1/S6K2
knockdown, which reduces S6K1 and S6K2 levels in Neuro2a
cells (Figures S5A and S5B), led to a reduction in the percentage
of transfected SVZ cells expressing pS6 and decreased NSC
soma size (Figures 5B and 5C), but it did not alter the frequency
of Mash1 or Ki67 expression (Figures 5D and S5E). Consistent
with these findings, coelectroporation of S6K1/S6K2 shRNA
with RhebCA prevented NSC cytomegaly but not the increased
frequency of Mash1+ cells and Ki67+ cells among transfected
cells induced by hyperactive mTORC1 (Figures 5D and S5C).438 Cell Reports 5, 433–444, October 31, 2013 ª2013 The AuthorsTo explore 4E-BP contribution, we employed an mTOR-resis-
tant, constitutively active 4E-BP1 plasmid (4E-BP1CA) (Figures
S5C and S5D), which constitutively binds eukaryotic initiation
factor 4E (eIF4E) and therefore mimics the effects of all endoge-
nous 4EBPs. 4E-BP1CA is thus expected to block cap-depen-
dent translation induced by hyperactive mTORC1 (Choi et al.,
2003). To determine whether 4E-BP1CA decreased cap-depen-
dent translation, NSCs were electroporated with a dual-lucif-
erase reporter plasmid that encodes both Renilla and firefly
luciferase. The Renilla luciferase is mediated by cap-dependent
translation, whereas the firefly luciferase is mediated by an inter-
mediate ribosome entry site (IRES). The Renilla/firefly luciferase
luminescence was calculated at 3 DPE following vector electro-
poration at P0. 4E-BP1CA significantly decreased cap-depen-
dent translational activity in the SVZ by 3 DPE (Figure 5J). As
Figure 5. 4E-BP and S6K1/S6K2 Regulate NSC Differentiation and Soma Size, Respectively
(A) Diagram illustrates the site of S6K1/S6K2 shRNA and 4E-BP1CA actions.
(B–D) Test shows S6K1/S6K2 shRNA alone and RhebCA condition. Bar graphs show the percentage (%) of transfected cells expressing pS6 (B), the normalized
NSC soma size (C), and the normalized percentage (%) of transfected cells expressing Mash1 (D) at 3 DPE under the conditions listed in the legend on the right.
(E) Bar graph shows Renilla/Firefly luciferase bioluminescence to measure cap-dependent translation levels from SVZ lysates 3 days following transfection of
pcDNA3-rLuc-PolioIRES-fLuc along with a vector encoding GFP (control), RhebCA, and RhebCA with 4E-BP1CA.
(F–H) Test presents 4E-BP1CA alone and RhebCA condition. Bar graphs show the percentage (%) of transfected cells expressing pS6 (F), the normalized NSC
soma size (G), and the normalized percentage (%) of transfected cells expressing Mash1 (G) at 3 DPE under the conditions listed in the legend on the right.
(I) Diagram illustrates the site of 4E-BP2 shRNA action and consequence on cap-dependent translation.
(J) Bar graph shows Renilla/Firefly luciferase bioluminescence to measure cap-dependent translation levels from SVZ lysate 3 days following transfection of
pcDNA3-rLuc-PolioIRES-fLuc along with a vector encoding scramble shRNA (control), 4E-BP1CA, 4E-BP2 shRNA, and 4E-BP1CA with 4E-BP2 shRNA.
(K) Bar graphs show the percentage (%) of RFP+ cells in the SVZ expressing Mash1 or Ki67 under control (Scr shRNA in black) and 4E-BP2 knockdown condition
(gray).
Asterisks indicate statistical significance (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) by one-way ANOVA or Student’s t test (n = 3–5 mice per condition).
Error bars are SEM. See also Figure S5.
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expected, RhebCA had the opposite effects and significantly
increased cap-dependent translational activity in the SVZ by 3
DPE (Figure 5E). Furthermore, when coexpressed with the
RhebCA, 4E-BP1CA was able to prevent RhebCA-induced in-
crease in cap-dependent luciferase luminescence (Figure 5E).
In contrast to S6K1/S6K2 knockdown, electroporation of 4E-
BP1CA alone in NSCs at P0 did not alter pS6 expression and
did not affect NSC soma size (Figures 5F and 5G). However,
4E-BP1CA decreased the percentage of Mash1+ TACs and
Ki67+ cells among transfected SVZ cells, similar to Rheb knock-
down (Figures 5H and S5E). In addition, 4E-BP1CA prevented the
increased differentiation of NSCs into Mash1+ TACs and thus
the Ki67+ cell generation induced by hyperactive mTORC1 (Fig-
ures 5H and S5E). Considering that 4E-BP2 is the major 4E-BP
expressed in the brain (Banko et al., 2005), we explored the
effect of 4E-BP2 knockdown on cap-dependent translation
and NSC differentiation in vivo using a shRNA targeted against
4E-BP2 (Figures S5F and S5G). Electroporation of 4E-BP2
shRNA at P0 increased cap-dependent translational activity in
the SVZ by 5 DPE as expected (Figures 5I and 5J). In addition,
4E-BP2 knockdown significantly increased the percentage of
Mash1+ TACs and Ki67+ cells among transfected SVZ cells at
5 DPE, similar to the hyperactive mTORC1 condition (Figure 5K).
Thus, knockdown of 4E-BP2, which leads to an increase in cap-
dependent translation, is sufficient to induce NSC differentiation.
DISCUSSION
Here, we have identified the physiological function of mTORC1
on neonatal NSC self-renewal. In particular, decreasedmTORC1
activity prevented NSC differentiation, leading to a reduced den-
sity of newborn neurons. In addition, we found that repression of
4E-BP activity by mTORC1, which results in an increase in cap-
dependent translation, is critical for NSC self-renewal and differ-
entiation. By contrast, mTORC1-activated S6K1/S6K2 regulated
NSC size but not differentiation, indicating different functions of
4E-BPs and S6K1/S6K2 on NSCs.
To decrease mTORC1 activity, we knocked down Rheb as
well as Raptor using shRNA and electroporation in neonates.
This approach allowed us to selectively transfect NSCs; it is
important to recognize that the transfected plasmids are passed
on to the progeny of NSCs, including TACs and neuroblasts. We
found that constitutive expression of Rheb shRNA in NSCs and
thus TACs and neuroblasts was associated with decreased
newborn neuron density in the OB examined at 14 DPE. Using
a conditional shRNA vector in transgenic mice expressing Cre
in neuroblasts limited Rheb shRNA expression to neuroblasts.
This approach revealed that decreasing mTORC1 activity only
in neuroblasts did not affect the density of newborn neurons,
suggesting that decreasing mTORC1 activity in NSCs/TACs
is responsible for decreased neuron production. We next
dissected the effects of mTORC1 activity in NSCs by examining
the frequency of transfected cells expressing the TAC marker
Mash1 and the proliferative marker Ki67 at 3 DPE as well as
the percentage of transfected NSCs that proliferate. In 3 days,
NSCs self-renewed and generatedMash1+ TACs, most of which
(>90%) are proliferative. In decreased mTORC1 condition, fewer
Mash1+ cells were generated, explaining the decreased neuron440 Cell Reports 5, 433–444, October 31, 2013 ª2013 The Authorsproduction. Consistent with these data, rapamycin treatment
decreased the number of Mash1+ and Ki67+ cells in the SVZ,
as previously reported by Paliouras et al. (2012). However, we
found that the proliferative status of Mash1+ TACs expressing
Rheb shRNA was not changed, suggesting that decreased
mTORC1 activity did not prevent TAC proliferation, which was
previously suggested. Rather, we propose that reduced
mTORC1 prevents NSC differentiation into TACs because in
the hyperactive mTORC1 condition, more Mash1+ TACs were
generated, and the proliferative index of transfected NSCs was
not affected. Thus, mTORC1 activity does not induce NSCs to
enter the cell cycle but, rather, is a regulator of their differentia-
tion into their daughter cells: Mash1+ TACs in the neonatal
SVZ. Our finding explains the loss of NSCs with aging that is
associated with increased mTORC1 (Johnson et al., 2013).
High levels of mTORC1 activity over time would lead to NSC
terminal differentiation and thus exhaustion.
Using similar approaches, we next identified that S6K1/S6K2
regulates NSC soma size, but not differentiation. Cell size regu-
lation is a conserved function of S6K and S6 phosphorylation
(Ruvinsky and Meyuhas, 2006; Montagne et al., 1999) and is
not commonly affected by 4E-BPs in mammalian cells (Dowling
et al., 2010). The sole contribution of 4E-BPs, and more specif-
ically 4E-BP2, to mTORC1-regulated NSC differentiation was
unpredicted but places 4E-BP2 as a key determinant of NSC dif-
ferentiation versus amplification and, thus, neuronal density and
brain size. In addition, although we cannot completely rule out an
increase in transcription in the RhebCA condition, the direct
manipulations of 4E-BP activity suggest that cap-dependent
translation, monitored by luciferase activity in vivo, is involved
in regulating NSC self-renewal at baseline and under hyperactive
mTORC1 condition.
The activity of mTORC1-4E-BP2 is affected by many environ-
mental conditions or mutations in the PI3K signaling pathway in
tumors and several neurological disorders (e.g., tuberous scle-
rosis complex, autism spectrum disorders, and hemimegalence-
phaly) (Dunlop and Tee, 2009; Tee and Blenis, 2005; Zoncu et al.,
2011; Laplante and Sabatini, 2012; Levitt and Campbell, 2009;
Lee et al., 2012). These disorders affect brain development
and are associated with mild-to-severe cognitive and psychiatric
impairments. We thus propose that 4E-BP2 is a target of choice
for preventing or rescuing abnormal brain development in infants
during perinatal life. In addition, future therapies could direct
tumor differentiation by developing molecules to switch on or
off 4E-BP2 activity on cap-dependent translation.EXPERIMENTAL PROCEDURES
Animals
Research protocols were approved by the Yale University Institutional Animal
Care and Use Committee. Experiments were performed on littermate wild-
type CD1 mice (Charles River), and transgenic hGfap-GFP mice and Dlx5/
Dlx6-Cre mice (The Jackson Laboratory).
Slice Preparation, Immunostaining, and Antibodies
Slice preparation and immunostaining were performed as previously
described (Lafourcade et al., 2013; Feliciano et al., 2012). Primary antibodies
were as follows: rabbit anti-pS6 (1:500 S240/244, no.5364; Cell Signaling);
rabbit anti-p4E-BP1/BP2 (1:200 Thr37/46, no.2855; Cell Signaling); mouse
Table 1. List of Vectors
Vectors Origin
CAG Promoter
GFP Addgene no.1150
tdTomato = RFP Pathania et al. (2012)
RhebCA Dr. Hanada, Tokyo (Maehama et al., 2008)
mTOR-resistant 4E-BP1 = 4E-BP1CA synthesized the gene with a Phe113 to Ala point mutation previously reported in Choi et al. (2003)
and inserted it into the Rheb encoding vector following excision of Rheb
A Cre/LoxP conditional RFP (pCALNL-RFP
for dsRed2)
Addgene no.13769 for dsRed (Matsuda and Cepko, 2007)
Cre Addgene no.13775
Blue fluorescent protein (BFP) Dr. Joshua J. Breunig, Cedars-Sinai (Breunig et al., 2012)
Conditional U6 Promoter Encoding shRNA (pSico no.11578 or pSicoR no.12084; Ventura et al., 2004)
Rheb shRNA (backbone vector) Sigma-Aldrich/RNAi consortium, Broad institute
target sequence, CCCGTCATCCTTGAAGATAAA
Scrambled shRNA Young et al., 2012
Raptor shRNA sequence from Broad Institute (Clone ID, TRCN0000077472)
S6K1/S6K2 shRNA Target sequence, CTCAGTGAGAGTGCCAACCAA from Bae et al. (2012)
4E-BP2 shRNA Sigma-Aldrich/RNAi consortium, Broad institute
target sequence (Clone ID, TRCN0000321000)
Luciferase (Luc) Reporter Vector
pcDNA3-rLuc-PolioIRES-fLuc (Renilla and
firefly Luc, rLuc, and fLuc)
John Blenis (Roux et al., 2007) originally provided by Dr. Bitterman (University of Minnesota)or rabbit anti-GFAP (1:500; Sigma-Aldrich or Dako); mouse anti-Mash1 (1:200;
BD Biosciences); mouse or rabbit anti-Ki67 (1:200 or 1:250; BD Biosciences
and Vector, respectively); chicken anti-GFP (1:500 ab13970; Abcam); and
guinea pig anti-DCX (1:1500; Millipore). EdU staining was performed using
the Click-iT Kit (Life Technologies) followed by the primary antibody staining
protocol. Immunostaining of cell cultures was performed by briefly washing
dishes with PBS and fixing in 4% paraformaldehyde for 15 min. After three
washes in PBS, cells were blocked with 2% BSA in 0.1% PBS-Triton X-100.
Cells were washed five times and incubated overnight in blocking buffer (2%
BSA in PBS) at 4C on an orbital shaker. Dishes were washed five times in
PBS, and secondary antibodies in blocking buffer were added for 1 hr at
room temperature. Dishes were washed five more times in PBS and counter-
stained with DAPI (1:5,000) for 5 min before washing three times in PBS and
mounting a coverslip with ProLong Gold antifade reagent. Each staining was
replicated in three to four slices from at least three different mice. Z section
images were acquired on a confocal microscope (Olympus FluoView 1000)
with a 203 dry objective (N.A. 0.75). Low-magnification images were acquired
with a 103 dry objective or a dissecting scope (SZX16 with a 13 objective).
Images were reconstructed using ImageJ 1.39t software (Wayne Rasband,
NIH) or Photoshop CS3.
For pS6 and p4E-BP1/BP2 immunohistochemical analyses, identical set-
tings for imaging were set between the two conditions, and staining above
background of the no primary controls was used to identify cells as positive
for either p4E-BP or pS6. The number of positive cells was then used to
analyze effects of mTORC1 inhibition and hyperactivation in the SVZ.
Neonatal Electroporation
Electroporation was performed as we previously described (Platel et al., 2010;
Lacar et al., 2010; Feliciano et al., 2012, 2013a). Plasmids (1–2 mg/ml) were
diluted in PBS containing 0.1% fast green as a tracer. A total of 0.5–1 ml of
plasmid solution was injected into the lateral ventricles of cold-anesthetized
neonatal pups using a pulled glass pipette (diameter <50 mm). Five square
pulses of 50 ms duration with 950 ms intervals at 100 V were applied using a
pulse ECM830 BTX generator and tweezers-type electrodes (model 520;
BTX) placed on the heads of P0-P1 pups.CVectors
shRNAs were inserted into the HpaI/XhoI sites in the pSico or pSicoR vectors
(Addgene; Ventura et al., 2004). A control shRNA was a scrambled sequence
that did not complement any known gene using a BLAST search. pSico con-
tains a U6 promoter preceding a Stop sequence containing enhanced GFP
flanked by LoxP sites prior to the shRNA sequence. pSico was coinjected
with pCAG-RFP and pCAG-Cre. The other vectors and their sources are listed
in Table 1.
Cell Counts in the SVZ and In Vivo Cell Density Measurement
Z stack images of the lateral wall of the SVZ in coronal sections were acquired
with a 203 dry objective using high-low settings to minimize saturation.
Images were reconstructed and were manually counted for each cell marker
using ImageJ 1.39t software. DAPI was routinely used as a counterstain to
count the percentage of SVZ cells expressing a specific marker. Three to
four sections containing the SVZ from a minimum of three mice per condition
were analyzed. For cell density measurements, confocal z stacks of serial cor-
onal sections were acquired at 103. ImageJ (NIH) was used to count cells in a
given volume to calculate cell density. Each image was adjusted for threshold
and analyzed for particles greater than 20 mm2 with a circularity between 0.5
and 1.0. All cells were counted in three different OB sections in a randomly
selected series from each animal. At least three animals were analyzed per
condition.
Neuro2a Cell Culture, Transfection, Western Blots, and Antibodies
The Neuro2a mouse neuroblastoma cell line (American Type Culture Collec-
tion) was propagated in tissue culture-treated polystyrene multiwell plates or
flasks (Falcon; BD Biosciences Discovery Labware). The growth medium con-
sisted of DMEM (Invitrogen) supplementedwith 10%heat-inactivated fetal calf
serum and penicillin-streptomycin at 100 U/l and 100 mg/l each (Invitrogen).
Cells were maintained at 37C and 5% CO2. PolyJet (SignaGen Laboratories)
was used to transfect expression vectors according to the instructions of the
manufacturer when cells reached 80% confluency. For transfection of shRNA
against S6K1/S6K2, nucleofection of the vectors with protocols designed by
Amaxa specifically for Neuro2a cells was used. Briefly, 1.53 106 Neuro2a cellsell Reports 5, 433–444, October 31, 2013 ª2013 The Authors 441
per condition were resuspended in 100 ml of Nucleofector Solution and 2 mg of
vector DNA. Cells were transfected using program T-024 in the Amaxa
Nucleofector II and plated into three wells of a 6-well plate in Neuro2a growth
media. RNA and protein were harvested 48 hr after transfection.
For western blots, samples were homogenized in 300 ml of RIPA buffer, 13
Halt Protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific),
and 8 U/ml DNase. Samples were boiled in 23 Laemmli’s buffer for 5 min.
Approximately 20 mg protein/sample was loaded into a 4%–15% polyacryl-
amide gel (Bio-Rad Mini Protean TGX gel). Proteins were transferred to
PVDF and blocked in 5% milk or 5% BSA. When appropriate, the blots were
probed for pS6 or other antibodies, stripped with Restore Western Stripping
Buffer from Pierce (catalog no.21059), followed by probing for ERK1/2. All
quantifications were performed using NIH ImageJ software. Antibodies for
western blots included the following: anti-pS6240/244 (1:10,000, catalog
no.5368; Cell Signaling Technology); anti-Raptor (1:5,000; Cell Signaling Tech-
nology); anti-Rheb (1:5,000; Thermo Scientific); anti-pS6K1 (1:2,000; Cell
Signaling); anti-S6K1 (1:3,000, catalog no.2708; Cell Signaling Technology);
anti-S6K2 (1:3,000; Bethyl Laboratories); rabbit anti-4E-BP1 (1:25,000
53H11; Cell Signaling); anti-4E-BP2 (1:5,000; Cell Signaling Technology);
and rabbit anti-ERK1/2 (1:20,000; Santa Cruz Biotechnology). HRP-conju-
gated donkey anti-rabbit from SouthernBiotech was used as secondary anti-
body (1:5,000).
NSC Culture
Protocols for primary NSC culture were based on previous studies by Ortega
et al. (2011) andCosta et al. (2011). Briefly, P0–P1 pupswere electroporated as
above. Twelve hours following electroporation, pups were anesthetized,
decapitated, and brains were placed in ice-cold Dissection Media (HBSS
with 10 mM HEPES) and cut into 400 mm coronal sections on a vibratome.
Using a No. 11 scalpel, the electroporated SVZ was dissected away from
the tissue and placed into 10 ml of ice-cold Dissection Media. After a brief
spin (200 3 g for 5 min), SVZ sections were resuspended in 5 ml Dissociation
Media (0.7 mg/ml trypsin and 0.7 mg/ml hyaluronidase in Solution 1 [HBSS
with 2.7% glucose and 15 mM HEPES]). Sections were incubated for 30 min
at 37C with one gentle trituration at 15 min. Sections were then resuspended
with 5 ml ice-cold Solution 3 (EBSS with 4% BSA and 20 mM HEPES) and
passed through a 70 mm pore cell strainer. Cells were spun down at 200 3 g
for 10 min. Cells were resuspended in 10 ml ice-cold Solution 2 (HBSS with
0.9 M D-(+)-saccharose) and spun again for 10 min at 450 3 g. Cells were re-
suspended in ice-cold Solution 3 and spun down at 250 3 g for 10 min. Cells
were resuspended in NSC Culture Media (DMEM/F12 supplemented with 13
B27, 13 penicillin/streptomycin, 13 GlutaMAX, and 8 mM HEPES) and plated
on poly-d-lysine (1mg/ml)-coated glass bottom dishes (MatTek; no.P35G-1.5-
14-C) at 200–300 cells/mm2. Media were changed the following day and every
other thereafter.
Quantification of Cap-Dependent Translation
Experiments were as previously reported using a luciferase reporter for
measuring HIF1A transcriptional activity (Feliciano et al., 2013c). Mice were
electroporated with a bicistronic luciferase reporter plasmid, pcDNA3-rLuc-
PolioIRES-fLuc, with pCAG-Rheb or a control pCAG-GFP vector. The reporter
vector directs cap-dependent translation of the Renilla luciferase gene and
the cap-independent Polio IRES-mediated translation of the firefly luciferase
gene (Roux et al., 2007; Kru¨ger et al., 2001). SVZ-containing transfected cells
at 3 DPE were microdissected and flash frozen in liquid nitrogen. Samples
were then placed in 0.1 ml ice-cold lysis buffer and subjected to the luciferase
assay (Promega) according to the manufacturer’s recommendations. Tissue
was incubated in a thermomixer for 15 min, shaken at 800 rpm at 23C.
Samples were centrifuged at 10,000 3 g for 10 min at 4C. The supernatant
was then placed on ice for 15 min. A total of 30 ml of sample was preloaded
into 100 ml of luciferase assay substrate and briefly mixed. The luminescence
was measured in a TD 20/20 Luminometer (Turner Designs). Measurements
were performed in duplicate or triplicate from at least four mice. Illustrated
data represent the normalized luminescence from Renilla luciferase divided
by that of Firefly luciferase. The different controls did not show any statistical
difference, and data were pooled together (e.g., for 4E-BP1CA alone and
RhebCA plus 4E-BP1CA).442 Cell Reports 5, 433–444, October 31, 2013 ª2013 The AuthorsSoma Size Measurement
Tomeasure cell size, z stack images of RFP+ or GFP+ cells in coronal sections
were acquired with a 203 dry objective (Numerical Aperture, 0.75) using high-
low settings to minimize saturation. In ImageJ, the freehand tracing tool was
used to outline cell somas.
Drug Treatments
Rapamycin (0.5 mg/kg) was given as intraperitoneal injections, one every other
day, to wild-type P5 pups until P9 or for RhebCA rescue experiments, immedi-
ately following electroporation, and every other day until sacrifice. EdU was
dissolved in DMSO, diluted to 5% DMSO 20 mg/ml EdU in PBS, and given
as intraperitoneal injections (50 mg/kg) 2 hr prior to sacrifice.
Statistics
Data were presented in Origin 8.0. Statistical significance was determined
using unpaired Student’s t test, one-way ANOVA, or Fisher’s exact test with
p < 0.05 for significance (KyPlot 2.0 or GraphPad Prism). Data are presented
as mean ± SEM.
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